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Abstract
The anticancer properties of Vitamin C (ascorbic acid o sodium ascorbate) are known since at least four decades,
However, being a cheap and "natural" product, Vitamin C is not patentable and therefore has never been developed
as an anticancer molecule.
Recent in vitro investigations have confirmed the extraordinary antitumor properties of high doses of Vitamin C
(sodium ascorbate), particularly when administered by the intravenous route, and phase I/II randomized, controlled
clinical trials have been started to verify its anticancer properties in vivo.
Unfortunately, the controlled clinical trials performed so far, do not confirm the extraordinary results obtained with
Vitamin C (sodium ascorbate) in vitro. However, this may depend on a number of different factors, such as the
pharmaceutical preparation (Sodium ascorbate may be more suitable than buffered ascorbic acid), the schedule of
administration (slow infusion better than rapid infusion), tumor tissue oxygenation (Cancer tissue oxygenation is
lower that oxygenation of tumor cell lines, in vitro), etc., which deserve further in depth investigation.
Even with these limitations, Vitamin C (sodium ascorbate) in high doses, administered by intravenous route,
beyond being extremely effective in vitro, against a number of human tumor cell lines, is safe, has minimal
contraindications, improves the quality of life of patients, and is highly selective for cancer cells.
The Authors discuss these important aspects and suggest possible solutions to improve the in vivo anticancer
effects of Vitamin C (sodium ascorbate).
Keywords: Vitamin C; Ascorbic acid; Sodium ascorbate; Cancer;
Free radicals; Oxidative stress; Antioxidants; Redox molecules
Introduction
Ascorbate (Vitamin C) is ubiquitous. It is found throughout the
plant and animal kingdoms, where its roles are often not known or are
poorly understood [1].
Among its multiple physiological functions, ascorbate:
1. Helps in the metabolism of tyrosine, folic acid and tryptophan;
2. Increases the elimination of cholesterol;
3. Contributes to the synthesis of catecholamines;
4. Helps the body to absorb and breakdown histamine;
5. Enhances the absorption of non-heme iron;
6. Is essential for the synthesis of collagen (its most widely known
physiological function);
7. As an antioxidant, it neutralizes free radicals (it is a reducing
agent and a “scavenger” of free radicals);
8. Protects DNA from damage due to free radicals and mutagens;
9. Reduces the risk of premature death;
10. Fights off widespread environmental pollutants;
11. Prevents the development of nitrosamines [2]
Though ubiquitous, ascorbate is not produced by humans, guinea
pigs, some primates, a particular type of fruit eating bat, the majority
of fishes and birds [3], who depend on diet for the assumption and use
of this fundamental nutrient.
The anticancer properties of ascorbate are known since at least four
decades, but the interest for ascorbate as an anticancer “drug” has
recently revived, due to in vitro investigations showing that ascorbate
in high concentrations is highly toxic for a wide variety of human
tumour cell lines, while it is almost completely harmless for their
normal counterpart. However, the most recent clinical trials on
ascorbate in high concentration, administered by the intravenous
route, do not seem to confirm the in vitro efficacy. This is most
probably due to several different problems concerning the
pharmaceutical form, the administration schedule, and a number of
other problems, which are discussed in this review.
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How Much Vitamin C?
Most animals can synthesize their own requirements of Vitamin C,
but since humans cannot, they are totally dependent upon dietary
intake of this vitamin [4]. In fact, the vast majority of animals produce
their own requirement of Vitamin C, whose synthesis is greatly
enhanced during stress [5].
For example, control rats metabolize, each day, 1.8 mg of Vitamin C
per 100 mg body weight, while pentobarbital, 3-methylcholanthrene,
and chloretone-treated rats, produce about 10 mg/100 mg of body
weight [6].
A 70 kg goat (the average weight used in calculations for adult
males) will produce Vitamin C at 33 mg/kg/day or 2.31 g/day. Under
stress or disease, the goat can produce 190 mg/kg/day or 13.3 g of
vitamin C a day [7,8]. By extension, man, who does not produce
Vitamin C, should be supplemented with grams of the vitamin,
although the US and European dietary references, recommend daily
amounts in the order of milligrams [9-11].
This is a clear indication that RDAs are designed to prevent
deficiency disease, with a little nutrients to spare, but do not guarantee
an optimal health condition.
Given all the above, and the fact that “vitamin” is, by definition,
“any of various organic substances that are essential in minute
quantities” [12].
Vitamin C cannot properly be defined a “vitamin”, and the term
“ascorbate” should be preferred to define this simple substance, with
pleiotropic functions and benefits for human health and well-being.
Hypoascorbemia and Chronic Subclinical Scurvy: The
Source of Every Disease
According to Irwin Stone, a biochemist who studied in depth the
many functions and roles of ascorbate in man, a balanced diet alone,
can only effectively prevent scurvy, but cannot guarantee a good health
condition. On this ground, he coined the term “hypoascorbemia” to
define the inability of humans and a few other species, to synthesize
ascorbic acid because of the lack of the enzyme L-gulonolactone
oxidase (GLO) [13] as a consequence of an “inborn error of
carbohydrate metabolism” [14-16].
This defect, now very well-known and characterized [17], led Stone,
and other scientists, such as Linus Pauling [18,19] to hypothesize that
to be in good health man needs mega-doses (several grams a day),
rather than doses in the order of milligrams, as stated by the
Recommended Daily Allowances (RDAs) [20].
Interestingly enough, Stone also hypothesized that almost every
known disease (including cancer, degenerative and chronic diseases,
cardiovascular diseases, etc.) largely depend on inadequate intake of
ascorbate through food, and a consequent “hypoascorbemia”, leading
to the clinical condition he defined “Chronic Subclinical Scurvy” (CSS)
[21,22].
In 1982, in a letter addressed to the Nobel laureate Albert Szent-
Gyorgyi, Irwin Stone, wrote: “Because of the poor and inadequate full
correction of the human defective gene for GLO (too little daily
ascorbate intake), every cancer victim was born scorbutic, after a 9-
month intrauterine bout with scurvy. This poor correction, due to
grossly inadequate maternal daily intakes of ascorbate, continues
throughout the lifetime of the victims, exposing them constantly to the
deleterious physiological insults of Chronic Subclinical Scurvy (the
CSS Syndrome)…” [23].
Mega-Doses of Vitamin C and Cancer
The letter thus continued: “…This (Chronic Subclinical Scurvy) is a
large factor in the genesis of the cancer. Every cancer victim being
treated by orthodox oncologists suffers also from a bad case of the CSS
Syndrome. When the orthodox cut, burn, and poison techniques prove
too much, the cancer victims do not die solely from the cancer lesion,
but are pushed into their grave by the exacerbated uncorrected scurvy
that is always present. We and other workers in this field haven't really
realized the enormous size of daily dosage of ascorbate required for
therapy and survival in cancer!” [23,24].
Therefore, in 1982, it was already clear, at least to some scientists,
that:
1. Cancer (as well as many other chronic diseases) depends on an
insufficient intake of ascorbate and the consequent
hypoascorbemia, leading to CSS
2. Cancer development can be effectively treated by ascorbate
3. The doses of ascorbate to be used, in the treatment of cancer,
must be in the order of several grams per day, i.e. from 300 to
several thousand times the amount suggested by the RDAs
As a matter of fact, in 1974, Irwin Stone had already reported about
the treatment of leukemia with mega-doses of ascorbate [18].
In the same year, Cameron and Campbell published the results of a
clinical trial, showing that, in “untreatable” cancer patients, ascorbate
in high doses can bring about some significant improvement in
morbidity and mortality [25].
Two years later, Cameron and Pauling showed that the survival of
untreatable cancer patients increased by a factor of about 3 in the
majority of cases, and about 20 in 10% of them, under treatment with
10 grams of ascorbate per day, starting with the intravenous route,
followed by oral administration [26].
Later on, the same authors confirmed, in another article, that 10 or
more grams of ascorbate per day, significantly prolong the survival and
improve the quality of life of untreatable cancer patients [27].
The Mayo Clinic responded to the mentioned articles, with two
studies, but the first one, in spite of the recommendations of Cameron
and Pauling, included patients previously treated with radio-/
chemotherapy [28], and the authors themselves, regarding this first
study, wrote: “He [Linus Pauling] speculated that our study did not
replicate the strongly positive results reported, because the cytotoxic
drugs destroy the body’s protective mechanisms, and Vitamin C
probably functions largely by potentiating these mechanisms.
Although the scientific basis of this conclusion seemed to us obscure
(!), we could not disprove Dr. Pauling’s contention with the evidence
produced by our study”.
Regarding the second study, published in 1985 [29], while the
Author’s intention was to follow the standard methodology of the
randomized, double blind, placebo-controlled clinical trial, in the
“Method” section of the article, the Authors write: “The nature and
purpose of the study were fully discussed with each patient, with
specific emphasis on the fact that they would receive either Vitamin C
or an inert placebo …”; in other words, this study was not “double
blind”, as patients were fully aware of treatments used! The Authors
refused to send the raw data to Pauling and other Authors who
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requested them, but it seems reasonable to assume that informing
cancer patients that they could undergo a placebo treatment, is both
ethically questionable, and methodologically inappropriate!
Although so seriously flawed, both studies were accepted by the
scientific community as the proof of the inefficacy of Vitamin C in
fighting cancer.
In vitro Evidence of the Effectiveness of Ascorbate in
the Treatment of Cancer
In 2005, the proof that the accepted views of the inefficacy of high
doses of ascorbate to treat cancer was wrong, came from Chen and
Coll. who demonstrated that pharmacologic ascorbic acid
concentrations, selectively kill cancer cells by acting as a pro-drug to
deliver hydrogen peroxide (H2O2) to cancerous tissues [30,31], and a
number of different investigators, worldwide, demonstrated the in
vitro efficacy of ascorbate in inducing apoptotic/necrotic cell death of a
multitude of human tumor cell lines. A good summary of these
investigations is reported by Park [32].
We have investigated, ourselves, the effects of high concentrations of
ascorbate on retinoblastoma (Y79) [33], uveal melanoma (OCM1,
C918) [34], human promyelocytic leukemia (HL60) [35], and a
number of other human myeloid leukemia cell lines [36], and almost
invariably found that two hours of exposure to millimolar (mM)
concentrations of ascorbate, determines apoptotic/necrotic cell death
of up to 90% of the cells in culture, at concentrations ranging from 3 to
5 mM.
Interestingly enough, our results, contrary to what is currently
believed, demonstrate that ascorbate gets into cancer cells almost
immediately, after exposure, and exerts its cytotoxic effects within the
cell and not outside of it.
Anticancer Mechanisms of High Doses of Ascorbate
As previously mentioned, the work of Chen et al. [30,31] has largely
demonstrated that ascorbate in high concentrations is a pro-drug of
H2O2, even though the cytotoxic effects of the oxidation products of
ascorbate, was already known more than four decades ago [37-39].
Although it is known that H2O2 can have both positive (signaling)
and negative (damage) effects, depending on the amount, increased
levels of hydrogen peroxide within the cells, such as those produced by
the intravenous administration of high doses of ascorbate, can result in
oxidative stress and cause cellular damage [40].
However, the role of ascorbate as a pro-drug of H2O2, when
administered in high doses, has been questioned by different authors
[41-43], and other mechanisms have been advocated to explain the
anticancer properties of this nutrient. Among others:
1. Vitamin C oxidation products such as dehydroascorbic acid, 2,3 -
diketogulonic acid, and 5-methyl 1-3,4-dehydroxytetrone, all
degradation products of ascorbic acid, have demonstrated antitumor
activity [44-48]. The antitumor activity shown by these compounds
could be due to their ability to produce active molecular species that
inhibit tumor growth such as H2O2 and certain aldehydes.
2. Large amounts of Vitamin C may lead to depletion of aminoacids
essential for tumor growth [49].
3. Dehydroascorbic acid (the oxidized, non-ionic and more lipid
soluble form of ascorbate) may promote lipid peroxidation, and
secondary products of lipid peroxidation may, in turn, have an
inhibitory action on human malignant cell proliferation [50-53].
4. Dehydroascorbic acid itself may work as a mitotic inhibitor [54].
5. When provided in large quantities ascorbate enhances the
removal of sodium via the urine thereby reducing the level of sodium
ions in the serum. In fact, cancer usually shows a disturbed sodium/
potassium ratio [37].
6. Since it is known that in the process of prostaglandin
biosynthesis, the release of arachidonic acid from cell membrane
phospholipids is implicated as one of the synergistic signals leading to
cell proliferation, another possible role of ascorbate, in fighting cancer,
consists in the inhibition of prostaglandins of the two series in
carcinoma cells [55,56].
Ascorbate also controls tumor growth by at least two other
important, even if indirect, mechanisms: by promoting the collagen
synthesis, it reinforces the natural barrier against cancer infiltration
and metastatic spread [57,58] and by ensuring the correct working of
the immune system, it inhibit tumor growth and spread by enhancing
the natural defense mechanisms of immune surveillance against cancer
[59-61].
High Doses of Ascorbate in Cancer: Vain Promise or
Unaccaptable Truth?
The anticancer effects of ascorbate are known since at least 1952
[62], but, after the two Mayo clinic studies mentioned above [28,29],
the medical establishment has dismissed ascorbate as ineffective
against cancer.
However, as we have seen in the previous sections, both the Mayo
Clinic studies were seriously flawed: the first one [28] by admission of
the Authors themselves, and the second one [29], not only because it
violated the requirements for a double blind clinical trial, but also
because:
• it used relatively low oral doses for short periods, rather than the
lifetime combination of high oral and intravenous (IV) doses, as in
the Cameron and Pauling study;
• it discontinued therapy as soon as the patient worsened;
• it enrolled only patients affected by colorectal cancer [63-65].
To add evidence to the work done by Cameron and Pauling,
Japanese researchers also found increased survival times similar, in
patients treated with Ascorbate [66,67], and Pauling himself reassessed
the survival rates of cancer patients treated with ascorbate, in 1990
[68], and 1993 [69], confirming the results of the former investigations,
even though both these papers have been largely ignored by the
scientific community.
Cameron and Campbell also tried to publish another article where
they demonstrated that the survival rate of terminal cancer patients
treated with ascorbate, is significantly higher than that of the controls,
but they couldn’t disseminate this knowledge as they would have [70].
Subsequently, Jackson and coll. reported their sixteen years-
experience with high doses of intravenous ascorbate in cancer and
other diseases, confirming that this treatment is safe and effective, for
cancer patients [71].
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Improving Ascorbate Treatment of Cancer
Current clinical evidence for a therapeutic effect of high-dose of
intravenous (IV) vitamin C has been defined “ambiguous”, and, despite
the forty years of research since the initial reports on high-dose of IV
ascorbate, its utility in fighting cancer remains controversial, at least, to
some authors .
To our opinion, this is a partial and biased view of the reality. While
many questions remain, concerning the efficacy of high doses of
ascorbate in vivo, including the optimal dose, timing, pharmaceutical
preparation, and combination with other antioxidants, a few firm
points remain, which represent a clear indication to the use of this
nutrient, in high IV concentration, to treat cancer; among others:
• It improves the quality of life of cancer patients [72]
• It prolongs their survival [26,27,73]
• It potentiates the cytotoxic effects and reduces the side effects of
conventional chemotherapy [74]
• It is remarkably safe in both physiologic, and pharmacologic
concentrations [75]
• It boosts the immune response, in cancer patients [76-79]
• It increases the host resistance to neoplasia [80,81]
• It protects against the development of neoplasia [82,83]
• It is an epigenetic modulator of genes with a key role in cancer
development [84,85]
• It is highly cytotoxic in vitro against a number of different human
tumor cell lines [30,31,33-36]
• It exert a powerful cytotoxic effect against colorectal cancer cells
refractory to targeted therapies [86,87].
The advantages of the use of high doses of intravenous ascorbate to
treat cancer, however, should not lead to overlook the many problems
that still remain to be solved, before translating the extraordinary in
vitro data into a clinical reality.
Conclusion
In the era of the “Evidence Based Medicine”, ascorbate is still
considered, by some Authors, ineffective in preventing and treating
cancer even though prominent scientists have demonstrated its
effectiveness in studies published on prestigious journals with high
Impact Factor (IF) [26,27].
Ironically, the “evidence” that has definitively dismissed ascorbate as
an anticancer molecule, is limited to the two articles published by the
Mayo Clinic oncologists which, as we have previously shown [29,30],
were both severely flawed even though published on a highly esteemed
journal
In very many ways, this is not surprising. Ascorbate is a cheap and
“natural” nutrient that, as such, cannot undergo any patent submission,
and no pharmaceutical company would ever invest on it to prevent or
cure cancer. This is, according to our opinion, the only reason why
ascorbate is still waiting for a definitive allocation within the
therapeutic tool bag of anticancer “drugs”, even though its effectiveness
is very well known since at least more than half a century.
The anticancer effects of ascorbate in vivo, most probably depend on
a number of variables which deserve further investigation; among
others:
• The pharmaceutical preparation (ascorbic acid may be more
difficult to handle than sodium ascorbate) [88]
• The time and schedule of administration (slow infusion to be
preferred) [89-91]
• The level of tissue oxygenation (cell cultures are better oxygenated
than tumor tissues, and this may explain the differences in the
outcomes of treatment of cancer cells in vitro, as compared to in
vivo studies) [92]
• The level of blood glucose (glucose may interfere with the uptake
of ascorbate by cancer cells [93,94].
All the above factors need to be further investigated, to optimize the
treatment of cancer with high doses of IV ascorbate, but even with
these limitations in mind, ascorbate is and remains the most powerful




• non-toxic for the body, even in high concentrations;
• highly toxic (and selective!) for cancer cells;
• completely harmless for their normal counterpart.
Is there anything new under the sun?
Ascorbate as an anticancer agent, has been around for at least four
decades, thanks to the passionate efforts of pioneers such as Albert
Szent-Gyorgyi, Frederik Klenner, Irwin Stone, Linus Pauling, Ewan
Cameron, and a few others; but the medical establishment could
hardly, and still cannot accept the idea that such a simple molecule, a
“nutrient”, could be so powerful in fighting cancer.
During these four decades, prominent scientists such as Linus
Pauling, have been often ridiculed by the medical establishment, for
their ideas and opinions regarding the role of Vitamin C in the
treatment of several diseases, including cancer, but, “… three things
cannot be hidden for a long time: the sun, the moon, and the truth!”.
In December 2015 [85], researchers have finally discovered that
ascorbate efficiently kills colon cancer cell, resistant to conventional
treatments; ironically, this demonstration pertains a cancer which
Creagan et al., at Mayo Clinic, found insensitive to ascorbate [30]!. An
epochal event is taking place in cancer treatment, but the
misunderstanding is always in ambush! The Authors of a related article
[84] conclude: “… Pauling may have been correct on the use of high
doses of Vitamin C for cancer therapy, but for wrong reasons – not as
an antioxidant, but as a pro oxidant anticancer agent”; knowing the
real story of Vitamin C, one can easily realize that this is simply not
true! Pauling never considered the anti- or pro- oxidant properties of
ascorbate; he rather pointed out its effects as a booster of the immune
response! The distinction itself, between anti- or pro- oxidant
properties of ascorbate, as related to the dose, may be misleading, since
ascorbate seems to behave differently not just according to its dose, but
rather according to the target cell, being an antioxidant for normal
cells, and pro- oxidant for cancer cells.
Almost a hundred years ago, Paul Erlich, the founder of modern
chemotherapy, who received the Nobel Prize for Physiology and
Medicine, hypothesized the creation of the “magic bullet” for use in the
fight against human disease, thus inspiring generations of scientists to
devise new powerful anticancer agents: today we know that the “magic
bullet” is here; ascorbate, in vitro is extremely effective and selective, as
we have demonstrated in leukemic cells lines and their normal
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counterpart [36] … to the clinical oncologists the endeavor and
responsibility to translate these wonderful data in a clinical
(revolutionary) reality!.
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